ArticleFrontiers in immunology2026
Timing of coffee consumption and insulin resistance: evidence from human and animal studies.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The role of coffee consumption timing in insulin resistance (IR), a key driver of cardiovascular-metabolic diseases, remains unclear. This study aimed to investigate the association between the timing of coffee consumption and IR in a large population-based study and animal experiments. Methods: This study comprised two phases. First, we performed a secondary data analysis of the US National Health and Nutrition Examination Survey (NHANES), involving a cross-sectional sample of 20,460 adults with complete dietary data. Temporal coffee consumption patterns were identified via two-step clustering and associated with insulin resistance indices using multivariable-adjusted regression models. Subsequently, findings were validated experimentally using mouse models. Results: Two distinct coffee consumption patterns were identified: morning-type (36%) and all-day-type (11%). After multivariable adjustment, only the morning-type pattern was significantly associated with lower IR indices (TyG: β = -0.04; METS-IR: β= -0.59; TG/HDL-C: β= -0.29) and a 17% lower risk of sever IR (OR = 0.83). Stratified analyses confirmed robustness across coffee intake levels. Notably, coffee consumption timing significantly modified the dose-response relationship between coffee intake amounts and IR indices. Morning-type showed a linear inverse relationship with IR indices, while all-day-type exhibited a J-shaped association. Mediation analysis revealed that inflammatory markers, specifically white blood cell (WBC) count and neutrophil-to-lymphocyte ratio (NLR), partially mediated the beneficial effects of morning coffee consumption on insulin resistance. In mice, morning coffee administration reduced fasting plasma glucose and serum insulin levels, improved glucose tolerance, and lowered proinflammatory cytokines (IL-1β, IL-6, ICAM-1, MCP-1). Conclusion: Drinking coffee in the morning may be more strongly associated with a lower insulin resistance than drinking coffee later in the day.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.